For decades, activists working to make dangerous drugs legal have been lying to the public – no surprise there, but they published their game plan.
They stated they were going to break down the public’s resistance to legalizing the use of all illegal drugs by starting with marijuana. Many thought that was no big deal, but meanwhile, users and growers have learned how to increase the THC content, making it much more potent … and increasingly dangerous, especially for youth.
First, they claimed the government did not allow the study of marijuana – a bold faced lie!
There are now tens of thousands of legitimate scientific studies showing the dangers, and the following information shows the studies continue. The following studies are so new, I suspect they’re not easily available on the net but you’ll be able to find at least the “abstracts” in the listed professional journals.
Following, you’ll find listed 180 scientific studies published last month alone – Sept.
Legalizers also began emulating “big tobacco” before the link to cancer was proven — buying off some M.D’s to claim there is no harm in using marijuana. Some went so far as to fund their own bogus studies.
Those of us who have lost loved ones to the tragedy of drug use have been working to try and get the truth to the public. Our attempts by-in-large have been thwarted by the liberal press who continues to lie and hide the truth, downplaying the damage done, while promoting full legalization.
Some activists are well paid for their work by the mega wealthy who want to control the markets; some are simply hedonists who want to ‘enjoy’ the use of their drug-of-choice w/o the stigma of arrest. Others are just simply evil!
Who will you believe? People working to save lives … or those with a self-serving agenda?
Sept. 2014 studies:
1. Treating drug dependence with the aid of ibogaine: A retrospective study. Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. / J Psychopharmacol. 2014 Sep 29. pii: 0269881114552713.
2. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P, Izzo AA. Carcinogenesis. 2014 Sep 30. pii: bgu205.
3. Perceived Harm, Addictiveness, and Social Acceptability of Tobacco Products and Marijuana Among Young Adults: Marijuana, Hookah, and Electronic Cigarettes Win. / Berg CJ, Stratton E, Schauer GL, Lewis M, Wang Y, Windle M, Kegler M. Subst Use Misuse. 2014 Sep 30.
4. Alteration of imprinted Dlk1-Dio3 miRNA cluster expression in the entorhinal cortex induced by maternal immune activation and adolescent cannabinoid exposure. Hollins SL, Zavitsanou K, Walker FR, Cairns MJ. / Transl Psychiatry. 2014 Sep 30;4:e452. doi: 10.1038/tp.2014.99.
5. The Moderating Effects of Sex and Age on the Association between Traumatic Brain Injury and Harmful Psychological Correlates among Adolescents. / Ilie G, Adlaf EM, Mann RE, Boak A, Hamilton H, Asbridge M, Colantonio A, Turner NE, Rehm J, Cusimano MD./ PLoS One. 2014 Sep 30;9(9):e108167. doi: 10.1371/journal.pone.0108167.
6. Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder. / Schuman-Olivier Z, Claire Greene M, Bergman BG, Kelly JF. / Drug Alcohol Depend. 2014 Sep 18. pii: S0376-8716(14)01071-0. doi: 10.1016/j.drugalcdep.2014.09.009.
7. Predicting Cannabis Abuse Screening Test (CAST) Scores: A Recursive Partitioning Analysis Using Survey Data from Czech Republic, Italy, the Netherlands and Sweden. / Blankers M, Frijns T, Belackova V, Rossi C, Svensson B, Trautmann F, van Laar M. PLoS One. 2014 Sep 29;9(9):e108298. doi: 10.1371/journal.pone.0108298.
8 Endocannabinoids Control Platelet Activation and Limit Aggregate Formation under Flow. / De Angelis V, Koekman AC, Weeterings C, Roest M, de Groot PG, Herczenik E, Maas C. PLoS One. 2014 Sep 29;9(9):e108282. doi: 10.1371/journal.pone.0108282.
9. Relationship between menarche and psychosis onset in women with first episode of psychosis. / Rubio-Abadal E, Usall J, Barajas A, Carlson J, Iniesta R, Huerta-Ramos E, Baños I, Dolz M, Sánchez B; GENIPE Group, Ochoa S. / Early Interv Psychiatry. 2014 Sep 27. doi: 10.1111/eip.12194.
10. Nonmedical stimulant use among young Asian-Americans, Native Hawaiians/Pacific Islanders, and mixed-race individuals aged 12-34 years in the United States. / Wu LT, Swartz MS, Brady KT, Blazer DG, Hoyle RH; NIDA AAPI Workgroup. / J Psychiatr Res. 2014 Sep 16. pii: S0022-3956(14)00271-4. doi: 10.1016/j.jpsychires.2014.09.004.
11. Long-term cannabis abuse and early-onset cannabis use increase the severity of cocaine withdrawal during detoxification and rehospitalization rates due to cocaine dependence. / Viola TW, Tractenberg SG, Wearick-Silva LE, Rosa CS, Pezzi JC, Grassi-Oliveira R. Drug Alcohol Depend. 2014 Sep 16. pii: S0376-8716(14)01065-5. doi: 10.1016/j.drugalcdep.2014.09.003.
12. Underestimation of substance abuse in psychiatric patients by conventional hospital screening. Reidy LJ, Junquera P, Van Dijck K, Steele BW, Nemeroff CB. / J Psychiatr Res. 2014 Sep 10. pii: S0022-3956(14)00263-5. doi: 10.1016/j.jpsychires.2014.08.020.
13. Trajectories of Marijuana Use Beginning in Adolescence Predict Tobacco Dependence in Adulthood. / Brook JS, Lee JY, Brook DW. / Subst Abus. 2014 Sep 26:0.
14. Are cannabidiol and Δ<sup>9</sup> -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. / McPartland JM, Duncan M, Di Marzo V, Pertwee R. / Br J Pharmacol. 2014 Sep 26. doi: 10.1111/bph.12944.
15. [High prevalence of drug consumption and sexual risk behaviors in men who have sex with men.] / Folch C, Fernández-Dávila P, Ferrer L, Soriano R, Díez M, Casabona J. / Med Clin (Barc). 2014 Sep 22. pii: S0025-7753(14)00582-X. doi: 10.1016/j.medcli.2014.04.030. Spanish.
16. Prevalence of medical marijuana use in California, 2012. / Ryan-Ibarra S, Induni M, Ewing D. / Drug Alcohol Rev. 2014 Sep 26. doi: 10.1111/dar.12207.
17. Synthesis of [13C4]-labeled ∆9-Tetrahydrocannabinol and 11-nor-9-Carboxy-∆9-tetrahydrocannabinol as Internal Standards for Reducing Ion Suppressing/Alteration Effects in LC/MS-MS Quantification. / Karlsen M, Liu H, Johansen JE, Hoff BH. / Molecules. 2014 Sep 1;19(9):13526-40. doi: 10.3390/molecules190913526.
18. Sedative-hypnotics are widely abused by drivers apprehended for driving under the influence of drugs. / Kriikku P, Hurme H, Wilhelm L, Rintatalo J, Hurme J, Kramer J, Ojanperä I. / Ther Drug Monit. 2014 Sep 24.
19. Neurophysiological evidence for the presence of cannabinoid CB1 receptors in the laterodorsal tegmental nucleus. / Soni N, Satpathy S, Kohlmeier KA. / Eur J Neurosci. 2014 Sep 23. doi: 10.1111/ejn.12730.
20. Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience. / Bhattacharyya S, Falkenberg I, Martin-Santos R, Atakan Z, Crippa JA, Giampietro V, Brammer M, McGuire P. / Neuropsychopharmacology. 2014 Sep 24. doi: 10.1038/npp.2014.258.
21. Cannabis, cannabidiol, and epilepsies: The truth is somewhere in the middle. / Sirven JI. / Epilepsy Behav. 2014 Sep 20. pii: S1525-5050(14)00429-6. doi: 10.1016/j.yebeh.2014.09.006.
22. Adherence to antiretroviral therapy during pregnancy and the first year postpartum among HIV-positive women in Ukraine. / Bailey H, Thorne C, Malyuta R, Townsend CL, Semenenko I, Cortina-Borja M; Ukraine European Collaborative Study Group in EuroCoord. / BMC Public Health. 2014 Sep 24;14:993. doi: 10.1186/1471-2458-14-993.
23. Nabilone therapy for cannabis withdrawal presenting as protracted nausea and vomiting. / Lam PW, Frost DW. / BMJ Case Rep. 2014 Sep 22;2014. pii: bcr2014205287. doi: 10.1136/bcr-2014-205287.
24. Attitudes Associated with Alcohol and Marijuana Referral Actions by Resident Assistants. / Thombs DL, Osborn CJ, Rossheim ME, Suzuki S. / J Prim Prev. 2014 Sep 23.
25. [Prevalence and Correlates of Substance Use in 5 688 Vocational School Students.] / Montag J, Hanewinkel R, Morgenstern M. / Gesundheitswesen. 2014 Sep 22. German.
26. [Does the use of cannabis increase the risk for psychosis and the development of schizophrenia?]. / Jonsson AJ, Birgisdottir H, Sigurdsson E. Laeknabladid. 2014 Sep;100(9):443-51. Icelandic.
27. [Cannabis is not harmless]. / Briem N. / Laeknabladid. 2014 Sep;100(9):441. Icelandic.
28. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. / Takematsu M, Hoffman RS, Nelson LS, Schechter JM, Moran JH, Wiener SW. / Clin Toxicol (Phila). 2014 Sep 20:1-3.
29. Heavy alcohol use, marijuana use, and concomitant use by adolescents are associated with unique and shared cognitive decrements. / Winward JL, Hanson KL, Tapert SF, Brown SA. / J Int Neuropsychol Soc. 2014 Sep;20(8):784-95. doi: 10.1017/S1355617714000666.
30. Association between interleukin-6 and neurocognitive performance as a function of self-reported lifetime marijuana use in a community based sample of african american adults. / Keen L, Turner AD. / J Int Neuropsychol Soc. 2014 Sep;20(8):773-83. doi: 10.1017/S1355617714000691.
31. Reliability and validity of the Marijuana Motives Measure among young adult frequent cannabis users and associations with cannabis dependence. / Benschop A, Liebregts N, van der Pol P, Schaap R, Buisman R, van Laar M, van den Brink W, de Graaf R, Korf DJ. / Addict Behav. 2014 Sep 9;40C:91-95. doi: 10.1016/j.addbeh.2014.09.003.
32. Adolescent marijuana users have elevated risk-taking on the balloon analog risk task. / Hanson KL, Thayer RE, Tapert SF. J Psychopharmacol. 2014 Sep 18. pii: 0269881114550352.
33. Resting state functional magnetic resonance imaging reveals distinct brain activity in heavy cannabis users – a multi-voxel pattern analysis. / Cheng H, Skosnik P, Pruce B, Brumbaugh M, Vollmer J, Fridberg D, O’Donnell B, Hetrick W, Newman S. / J Psychopharmacol. 2014 Sep 18. pii: 0269881114550354.
34. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. / Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, Dos Santos AC, Teixeira AL, Hallak JE, Crippa JA. / J Psychopharmacol. 2014 Sep 18. pii: 0269881114550355.
35. Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report. / Qian HZ, Mitchell VJ, Bebawy S, Cassell H, Perez G, McGowan CC, Sterling TR, Vermund SH, D’Aquila R, Hulgan T. / BMC Infect Dis. 2014 Sep 18;14:508. doi: 10.1186/1471-2334-14-508.
36. The effects of purchasing alcohol and marijuana among adolescents at-risk for future substance use. / Osilla KC, Pedersen ER, Ewing BA, Miles JN, Ramchand R, D’Amico EJ. / Subst Abuse Treat Prev Policy. 2014 Sep 18;9(1):38. doi: 10.1186/1747-597X-9-38.
37. Positive mental health and mental illness. / Gilmour H. / Health Rep. 2014 Sep 17;25(9):3-9.
38. Screening and brief intervention for unhealthy drug use: little or no efficacy. / Saitz R. / Front Psychiatry. 2014 Sep 2;5:121. doi: 10.3389/fpsyt.2014.00121.
39. Evaluating the role of a galanin enhancer genotype on a range of metabolic, depressive and additive phenotypes. / Richardson TG, Minica C, Heron J, Tavare J, MacKenzie A, Day I, Lewis G, Hickman M, Vink JM, Gelernter J, Kranzler HR, Farrer LA, Munafò M, Wynick D. / Am J Med Genet B Neuropsychiatr Genet. 2014 Sep 16. doi: 10.1002/ajmg.b.32270.
40. Medical marijuana: more questions than answers. Hill KP. / J Psychiatr Pract. 2014 Sep;20(5):389-91. doi: 10.1097/01.pra.0000454786.97976.96.
41. Cannabinoid-induced actomyosin contractility shapes neuronal morphology and growth. / Roland AB, Ricobaraza A, Carrel D, Jordan BM, Rico F, Simon A, Humbert-Claude M, Ferrier J, McFadden MH, Scheuring S, Lenkei Z. / Elife. 2014 Sep 15;3. doi: 10.7554/eLife.03159.
42. Alcohol and Marijuana Use in Middle School: Comparing Solitary and Social-Only Users. Tucker JS, Pedersen ER, Miles JN, Ewing BA, Shih RA, D’Amico EJ. / J Adolesc Health. 2014 Sep 13. pii: S1054-139X(14)00274-2. doi: 10.1016/j.jadohealth.2014.06.015.
43. Production, perceptions, and punishment: Restrictive deterrence in the context of cannabis cultivation. Nguyen H, Malm A, Bouchard M. / Int J Drug Policy. 2014 Sep 2. pii: S0955-3959(14)00226-6. doi: 10.1016/j.drugpo.2014.08.012.
44. The relative harms of marijuana and alcohol. Gorelick DA. / Am J Drug Alcohol Abuse. 2014 Sep 15:1-3.
45. Evaluation of underlying mechanisms in the link between childhood ADHD symptoms and risk for early initiation of substance use. Vitulano ML, Fite PJ, Hopko DR, Lochman J, Wells K, Asif I. / Psychol Addict Behav. 2014 Sep;28(3):816-27. doi: 10.1037/a0037504.
46. Synthetic Cannabinoids: Use and predictors in a Community Sample of Young Adults. Caviness CM, Tzilos G, Anderson BJ, Stein MD. / Subst Abus. 2014 Sep 15:0.
47. P-73an investigation of addictions (substances and behaviors) in a community sample. Deleuze J, Rochat L, Romo L, Van der Linden M, Thorens G, Khazaal Y, Rothen S, Achab S, Billieux J. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i68. doi: 10.1093/alcalc/agu054.73.
48. P-66characteristics of in-patients with ADHD and substance use disorder: a retrospective study. Altıntoprak E, Donuk T, Ozyurt B. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i66. doi: 10.1093/alcalc/agu054.66.
49. P-65substance abuse in psychiatric patients attending out patient department. Ghulam R, Jain R, Pal R, Sakpal V. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i66. doi: 10.1093/alcalc/agu054.65.
50. P-41protocols for subcutaneous flumazenil use in patients with benzodiazepine and alcohol addiction. O’Neil GA. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i61. doi: 10.1093/alcalc/agu054.41.
51. Sy03-2-5who-isam fellowship neurocognitive disorder on prisoners using cannabis in cipinang jakarta prison. Kurniasanti K, Alia D, Zyzlavsky S. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i6-i7. doi: 10.1093/alcalc/agu052.20.
52. Or15-1the gateway hypothesis, common liability to addictions or the route of administration model? An original modelling process linking the three theories. Mayet A, Legleye S, Beck F, Khlat M, Chau N, Falissard B. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i52. doi: 10.1093/alcalc/agu053.70.
53. Or14-1patterns and transitions in substance use among young swiss men. Baggio S, Studer J, Gmel G. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i51. doi: 10.1093/alcalc/agu053.65.
54. Sy03-1-3isam fellowship prevalence of hiv infection among the over 18 year old substance abusers in mwanza urban, Tanzania. Hauli KA, Kongola GW, Kalluvya SE, Jande MB, Majinge CR, Kapiga S, Konje E. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i5. doi: 10.1093/alcalc/agu052.12.
55. Or08-4how craving fluctuates – preliminary results of a longitudinal study among gamblers. Cornil AP, Billieux J. Alcohol Alcohol. 2014 Sep;49 Suppl 1:i45-i46. doi: 10.1093/alcalc/agu053.38.
56. Sy40-4cannabidiol: long-lasting amelioration of vulnerability States associated with relapse risk as determined in animal models of drug seeking, anxiety, and impulsivity. Weiss F, Martin-Fardon R, Gonzales-Cuevas G, Stinchcomb A. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i34. doi: 10.1093/alcalc/agu052.168.
57. Sy32-2common and specific genes that contribute to co-morbid disorders in alcoholism. Hesselbrock VM, Hesselbrock M. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i28. doi: 10.1093/alcalc/agu052.138.
58. Sy14-5cannabis use disorders: latest data on cannabinoid formulations, routes of administration and treatment. Haney M. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i14. doi: 10.1093/alcalc/agu052.63.
59. Sy14-2management of medical consequences of cannabis: research at national institute on drug abuse. Khalsa JH. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i14. doi: 10.1093/alcalc/agu052.62.
60. Sy14-3marijuana – the state of the United States. Gitlow S. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i14. doi: 10.1093/alcalc/agu052.60.
61. Sy14-4medical marijuana in new york state: theater of the absurd. Wetterau N. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i14. doi: 10.1093/alcalc/agu052.59.
62. Sy14-1global epidemiology of cannabis use and implications for public health. Poznyak V. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i14. doi: 10.1093/alcalc/agu052.58.
63. Sy13-1-4american society of addiction medicine – an annual review. Gitlow S. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i13. doi: 10.1093/alcalc/agu052.53.
64. Sy09-2harm reduction in substance related addictions. Zullino DF, Khan R, Thorens G, Achab S, Khazaal Y, Calzada G, Manghi R. / Alcohol Alcohol. 2014 Sep;49 Suppl 1:i11. doi: 10.1093/alcalc/agu052.42.
65. Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking. Lee D, Vandrey R, Mendu DR, Murray JA, Barnes AJ, Huestis MA. / Drug Test Anal. 2014 Sep 14. doi: 10.1002/dta.1718.
66. [Approche en soins primaires pour les problèmes de consommation de cannabis: Plein feu sur les jeunes et autres usagers à risque élevé] Turner SD, Spithoff S, Kahan M. / Can Fam Physician. 2014 Sep;60(9):e423-e432. French.
67. Approach to cannabis use disorder in primary care: Focus on youth and other high-risk users. Turner SD, Spithoff S, Kahan M. Can Fam Physician. 2014 Sep;60(9):801-808. Review.
68. [Le cannabis et les jeunes Canadiens: Les données probantes plutôt que l'idéologie.] Spithoff S, Kahan M. / Can Fam Physician. 2014 Sep;60(9):793-795. French.
69. Cannabis and Canadian youth: Evidence, not ideology. / Spithoff S, Kahan M. / Can Fam Physician. 2014 Sep;60(9):785-7.
70. [Cannabis.] Ladouceur R. / Can Fam Physician. 2014 Sep;60(9):776. French.
71. Cannabis. Ladouceur R. / Can Fam Physician. 2014 Sep;60(9):775.
72. Evidence That Environmental and Genetic Risks for Psychotic Disorder May Operate by Impacting on Connections Between Core Symptoms of Perceptual Alteration and Delusional Ideation. Smeets F, Lataster T, Viechtbauer W, Delespaul P; G.R.O.U.P.. / Schizophr Bull. 2014 Sep 12. pii: sbu122.
73. Inhaled medicinal cannabis and the immunocompromised patient. Ruchlemer R, Amit-Kohn M, Raveh D, Hanuš L. / Support Care Cancer. 2014 Sep 13.
74. Physicians, medical marijuana, and the law. Gregorio J. Virtual Mentor. 2014 Sep 1;16(9):732-8. doi: 10.1001/virtualmentor.2014.16.09.hlaw1-1409.
75. Allowing cigarette or marijuana smoking in the home and car: prevalence and correlates in a young adult sample. Padilla M, Berg CJ, Schauer GL, Lang DL, Kegler MC. / Health Educ Res. 2014 Sep 11. pii: cyu051.
76. Functional impairment in adolescents and young adults with emerging mood disorders. Scott J, Scott EM, Hermens DF, Naismith SL, Guastella AJ, White D, Whitwell B, Lagopoulos J, Hickie IB. / Br J Psychiatry. 2014 Sep 11. pii: bjp.bp.113.134262.
77. Relationship between seminal plasma levels of anandamide congeners palmitoylethanolamide and oleoylethanolamide and semen quality. Amoako AA, Marczylo TH, Elson J, Taylor AH, Willets JM, Konje JC. / Fertil Steril. 2014 Sep 8. pii: S0015-0282(14)01394-6. doi: 10.1016/j.fertnstert.2014.07.767.
78. Gender Abuse, Depressive Symptoms, and Substance Use Among Transgender Women: A 3-Year Prospective Study. Nuttbrock L, Bockting W, Rosenblum A, Hwahng S, Mason M, Macri M, Becker J. / Am J Public Health. 2014 Sep 11:e1-e8.
79. Parental alcohol history differentially predicts offspring disorders in distinct subgroups in Israel. Meyers JL, Shmulewitz D, Elliott JC, Thompson RG, Aharonovich E, Spivak B, Weizman A, Frisch A, Grant BF, Hasin DS. / J Stud Alcohol Drugs. 2014 Sep;75(5):859-69.
80. Gender differences in the developmental risk of onset of alcohol, nicotine, and marijuana use and the effects of nicotine and marijuana use on alcohol outcomes. Buu A, Dabrowska A, Mygrants M, Puttler LI, Jester JM, Zucker RA. / J Stud Alcohol Drugs. 2014 Sep;75(5):850-8.
81. Personality and the prediction of high-risk trajectories of alcohol use during adolescence. Peeters M, Monshouwer K, van de Schoot R, Janssen T, Vollebergh WA, Wiers RW. / J Stud Alcohol Drugs. 2014 Sep;75(5):790-8.
82. Momentary positive and negative affect preceding marijuana use events in youth. Shrier LA, Ross CS, Blood EA. / J Stud Alcohol Drugs. 2014 Sep;75(5):781-9.
83. Cortical thickness and neurocognition in adolescent marijuana and alcohol users following 28 days of monitored abstinence. Jacobus J, Squeglia LM, Sorg SF, Nguyen-Louie TT, Tapert SF. / J Stud Alcohol Drugs. 2014 Sep;75(5):729-43.
84. Risk Estimation Modeling and Feasibility Testing for a Mobile eHealth Intervention for Binge Drinking among Young People: The D-ARIANNA (Digital – Alcohol RIsk Alertness Notifying Network for Adolescents and young adults) Project. Carrà G, Crocamo C, Schivalocchi A, Bartoli F, Carretta D, Brambilla G, Clerici M. / Subst Abus. 2014 Sep 9:0.
85. Deception for drugs: self-reported “doctor shopping” among young adults. Stogner JM, Sanders A, Miller BL. / J Am Board Fam Med. 2014 Sep-Oct;27(5):583-93. doi: 10.3122/jabfm.2014.05.140107.
86. Prevalence and correlates of depersonalization in students aged 12-18 years in Germany. Michal M, Duven E, Giralt S, Dreier M, Müller KW, Adler J, Beutel ME, Wölfling K. / Soc Psychiatry Psychiatr Epidemiol. 2014 Sep 9.
87. St8sia2 deficiency plus juvenile cannabis exposure in mice synergistically affect higher cognition in adulthood. Tantra M, Kröcher T, Papiol S, Winkler D, Röckle I, Jatho J, Burkhardt H, Ronnenberg A, Gerardy-Schahn R, Ehrenreich H, Hildebrandt H. / Behav Brain Res. 2014 Sep 6;275C:166-175. doi: 10.1016/j.bbr.2014.08.062.
88. Medical Marijuana for Digestive Disorders: High Time to Prescribe? Gerich ME, Isfort RW, Brimhall B, Siegel CA. / Am J Gastroenterol. 2014 Sep 9. doi: 10.1038/ajg.2014.245.
89. Study of Leaf Metabolome Modifications Induced by UV-C Radiations in Representative Vitis, Cissus and Cannabis Species by LC-MS Based Metabolomics and Antioxidant Assays. Marti G, Schnee S, Andrey Y, Simoes-Pires C, Carrupt PA, Wolfender JL, Gindro K. Molecules. 2014 Sep 5;19(9):14004-21. doi: 10.3390/molecules190914004.
90. Using Web searches to track interest in synthetic cannabinoids (aka ‘herbal incense’). Curtis B, Alanis-Hirsch K, Kaynak O, Cacciola J, Meyers K, McLellan AT. Drug Alcohol Rev. 2014 Sep 6. doi: 10.1111/dar.12189.
91. Cannabis and related impairment: The unique roles of cannabis use to cope with social anxiety and social avoidance. Buckner JD, Zvolensky MJ. / Am J Addict. 2014 Sep 7. doi: 10.1111/j.1521-0391.2014.12150.x.
92. Discriminating the Effects of Cannabis sativa and Cannabis indica: A Web Survey of Medical Cannabis Users. Pearce DD, Mitsouras K, Irizarry KJ. / J Altern Complement Med. 2014 Sep 5.
93. [Cerebellar stroke by cannabis use.] Urbano Seguí J, Falcón Espínola L, Expósito Rodríguez M, Burillo-Putze G. / Med Clin (Barc). 2014 Sep 1. pii: S0025-7753(14)00509-0. doi: 10.1016/j.medcli.2014.06.007.
94. Patterns of medical marijuana use among individuals sampled from medical marijuana dispensaries in los angeles. Grella CE, Rodriguez L, Kim T. / J Psychoactive Drugs. 2014 Sep-Oct;46(4):263-72. doi: 10.1080/02791072.2014.944960.
95. The role of drug use sequencing pattern in further problematic use of alcohol, tobacco, cannabis, and other drugs. Castaldelli-Maia JM, Martins SS, de Oliveira LG, de Andrade AG, Nicastri S. /J Ment Health. 2014 Sep 4:1-6.
96. Factors associated with the timing and onset of cannabis use and cannabis use disorder: Results from the 2007 Australian National Survey of Mental Health and Well-Being. / Butterworth P, Slade T, Degenhardt L. Drug Alcohol Rev. 2014 Sep;33(5):555-64. doi: 10.1111/dar.12183.
97. Developmental Increase in Hippocampal Endocannabinoid Mobilization: Role of Metabotropic Glutamate Receptor Subtype 5 and Phospholipase C. / Liang SL, Alger BE, McCarthy MM. / J Neurophysiol. 2014 Sep 3. pii: jn.00111.2014.
98. MediData: How potent is medical marijuana? Collier R. / CMAJ. 2014 Sep 2. pii: cmaj.109-4856.
99. Health Risk Behavior Among Thai Youth: National Survey 2013. Sirirassamee T, Sirirassamee B. / Asia Pac J Public Health. 2014 Sep 1. pii: 1010539514548759.
100. Perceived neighborhood illicit drug selling, peer illicit drug disapproval and illicit drug use among U.S. high school seniors. Duncan DT, Palamar JJ, Williams JH. / Subst Abuse Treat Prev Policy. 2014 Sep 3;9(1):35. doi: 10.1186/1747-597X-9-35.
101. Correction: understanding cultivar-specificity and soil determinants of the cannabis microbiome. PLOS ONE Staff. / PLoS One. 2014 Sep 2;9(9):e107415. doi: 10.1371/journal.pone.0107415. eCollection 2014.
102. Expanding Medical Marijuana Access in Canada: Considerations for the Rheumatologist. Fitzcharles MA, Jamal S. J Rheumatol. 2014 Sep 1. pii: jrheum.131514.
103. Cannabis in the Treatment of Rheumatic Diseases: Suggestions for a Reasoned Approach. Kalant H. / J Rheumatol. 2014 Sep 1. pii: jrheum.140683.
104. [Severe rhabdomyolysis and intracranial hemorrhage associated with synthetic cannabinoid: a case report]. Tanei T, Morita Y, Yashima A, Wakita H, Takebayashi S, Nakahara N, Wakabayashi T. No Shinkei Geka. 2014 Sep;42(9):867-71. Japanese.
105. C-76The Impact of a Motivational Statement and Age of Cannabis Use Onset on Neuropsychological Test Performance. Sodos L, Young K, Teague A, Gretler J, Macher R. / Arch Clin Neuropsychol. 2014 Sep;29(6):602. doi: 10.1093/arclin/acu038.257.
106. Using Bayesian Models to Assess the Effects of Under-reporting of Cannabis Use on the Association with Birth Defects, National Birth Defects Prevention Study, 1997-2005. / van Gelder MM, Donders AR, Devine O, Roeleveld N, Reefhuis J; National Birth Defects Prevention Study. / Paediatr Perinat Epidemiol. 2014 Sep;28(5):424-33. doi: 10.1111/ppe.12140.
107. Changes in driver cannabinoid prevalence in 12 U.S. states after implementing medical marijuana laws. Masten SV, Guenzburger GV. / J Safety Res. 2014 Sep;50:35-52. doi: 10.1016/j.jsr.2014.03.009.
108. Application of item response theory to tests of substance-related associative memory. Shono Y, Grenard JL, Ames SL, Stacy AW. / Psychol Addict Behav. 2014 Sep;28(3):852-62. doi: 10.1037/a0035877.
109. Sexual-orientation disparities in substance use in emerging adults: A function of stress and attachment paradigms. Rosario M, Reisner SL, Corliss HL, Wypij D, Calzo J, Austin SB. / Psychol Addict Behav. 2014 Sep;28(3):790-804. doi: 10.1037/a0035499.
110. Couples’ marijuana use is inversely related to their intimate partner violence over the first 9 years of marriage. Smith PH, Homish GG, Collins RL, Giovino GA, White HR, Leonard KE. / Psychol Addict Behav. 2014 Sep;28(3):734-42. doi: 10.1037/a0037302.
111. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. Eisenberg E, Ogintz M, Almog S. / J Pain Palliat Care Pharmacother. 2014 Sep;28(3):216-25. doi: 10.3109/15360288.2014.941130.
112. Chronic Δ<sup>9</sup>-Tetrahydrocannabinol Administration May Not Attenuate Simian Immunodeficiency Virus Disease Progression in Female Rhesus Macaques. Amedee AM, Nichols WA, LeCapitaine NJ, Vande Stouwe C, Birke LL, Lacour N, Winsauer PJ, Molina PE. / AIDS Res Hum Retroviruses. 2014 Sep 5.
113. Correction to patrick et Al. (2013). Psychol Assess. 2014 Sep;26(3):805. doi: 10.1037/a0037809.
114. The prevalence of cannabis withdrawal and its influence on adolescents’ treatment response and outcomes: a 12-month prospective investigation. Greene MC, Kelly JF. /J Addict Med. 2014 Sep-Oct;8(5):359-67. doi: 10.1097/ADM.0000000000000064.
115. Medical marijuana, physicians, and state law. Annas GJ. / N Engl J Med. 2014 Sep 11;371(11):983-5. doi: 10.1056/NEJMp1408965.
116. Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: A brain stimulation reward study. Gallo A, Bouchard C, Fortier E, Ducrot C, Rompré PP. / Eur Neuropsychopharmacol. 2014 Sep;24(9):1534-45. doi: 10.1016/j.euroneuro.2014.07.003.
117. Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs. Batista LA, Gobira PH, Viana TG, Aguiar DC, Moreira FA. / Behav Pharmacol. 2014 Sep;25(5-6):425-33. doi: 10.1097/FBP.0000000000000073
118. Factors affecting noncompliance with buprenorphine maintenance treatment. Fareed A, Eilender P, Ketchen B, Buchanan-Cummings AM, Scheinberg K, Crampton K, Nash A, Shongo-Hiango H, Drexler K. / J Addict Med. 2014 Sep-Oct;8(5):345-50. doi: 10.1097/ADM.0000000000000057.
119. Evaluation of the initiation of urine drug screens intended for use in transfer patients. Vakkalanka P, Rushton WF, Hardison LS, Bishop MC, Haverstick DM, Holstege CP. / Am J Emerg Med. 2014 Sep;32(9):1037-40. doi: 10.1016/j.ajem.2014.06.011.
120. Patterns of tobacco smoking among illicit drug users in Australia 2001-2010. Fraser D, Gartner C, Hall W. / Drug Alcohol Rev. 2014 Sep;33(5):534-9. doi: 10.1111/dar.12187.
121. Examining potential school contextual influences on gambling among high school youth. Lee GP, Martins SS, Pas ET, Bradshaw CP. / Am J Addict. 2014 Sep-Oct;23(5):510-7. doi: 10.1111/j.1521-0391.2014.12142.x.
122. A structure-reactivity relationship driven approach to the identification of a color test protocol for the presumptive indication of synthetic cannabimimetic drugs of abuse. Isaacs RC. / Forensic Sci Int. 2014 Sep;242:135-41. doi: 10.1016/j.forsciint.2014.06.027.
123. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. / Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, Pál B, Ambrus L, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R, Bíró T. / J Clin Invest. 2014 Sep 2;124(9):3713-24. doi: 10.1172/JCI64628.
124. Prognosis of schizophrenia in persons with and without a history of cannabis use. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. / Psychol Med. 2014 Sep;44(12):2513-21. doi: 10.1017/S0033291714000191.
125. Cannabis use and transition to psychosis in people at ultra-high risk. Valmaggia LR, Day FL, Jones C, Bissoli S, Pugh C, Hall D, Bhattacharyya S, Howes O, Stone J, Fusar-Poli P, Byrne M, McGuire PK. Psychol Med. 2014 Sep;44(12):2503-12. doi: 10.1017/S0033291714000117.
126. Retrospective analysis of synthetic cannabinoids in serum samples – epidemiology and consumption patterns. Jaenicke NJ, Pogoda W, Paulke A, Wunder C, Toennes SW. / Forensic Sci Int. 2014 Sep;242:81-7. doi: 10.1016/j.forsciint.2014.06.010.
127. MediData: How many types of medical marijuana are for sale? Collier R. / CMAJ. 2014 Sep 16;186(13):E475. doi: 10.1503/cmaj.109-4847.
128. Prescribing marijuana? You have more than 200 options. Collier R. / CMAJ. 2014 Sep 2;186(12):E440. doi: 10.1503/cmaj.109-4849.
129. Reciprocal relations between perceived parental knowledge and adolescent substance use and delinquency: The moderating role of parent-teen relationship quality. Abar CC, Jackson KM, Wood M. / Dev Psychol. 2014 Sep;50(9):2176-87. doi: 10.1037/a0037463.
130. Unemployment and substance outcomes in the United States 2002-2010. Compton WM, Gfroerer J, Conway KP, Finger MS. / Drug Alcohol Depend. 2014 Sep 1;142:350-3. doi: 10.1016/j.drugalcdep.2014.06.012.
131. Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC. Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. / Schizophr Res. 2014 Sep;158(1-3):176-82. doi: 10.1016/j.schres.2014.04.033.
132. Assessing the connection between health and education: identifying potential leverage points for public health to improve school attendance. Gase LN, Kuo T, Coller K, Guerrero LR, Wong MD. / Am J Public Health. 2014 Sep;104(9):e47-54. doi: 10.2105/AJPH.2014.301977.
133. Cannabis poisoning in children. Le Garrec S, Dauger S, Sachs P. / Intensive Care Med. 2014 Sep;40(9):1394-5. doi: 10.1007/s00134-014-3395-4.
134. [Topiramate in substance-related and addictive disorders]. Cohen J, Dervaux A, Laqueille X. / Presse Med. 2014 Sep;43(9):892-901. doi: 10.1016/j.lpm.2014.02.030. French.
135. Are users’ most recent drug purchases representative? Bond B, Caulkins JP, Scott N, Kilmer B, Dietze P. / Drug Alcohol Depend. 2014 Sep 1;142:133-8. doi: 10.1016/j.drugalcdep.2014.06.016.
136. Fitness to drive and cannabis: Validation of two blood THCCOOH thresholds to distinguish occasional users from heavy smokers. Fabritius M, Augsburger M, Chtioui H, Favrat B, Giroud C. / Forensic Sci Int. 2014 Sep;242:1-8. doi: 10.1016/j.forsciint.2014.05.014.
137. Problematic substance use in urban adolescents: role of intrauterine exposures to cocaine and marijuana and post-natal environment. Frank DA, Kuranz S, Appugliese D, Cabral H, Chen C, Crooks D, Heeren T, Liebschutz J, Richardson M, Rose-Jacobs R. / Drug Alcohol Depend. 2014 Sep 1;142:181-90. doi: 10.1016/j.drugalcdep.2014.06.014.
138. A “refugee paradox” for substance use disorders? Salas-Wright CP, Vaughn MG. / Drug Alcohol Depend. 2014 Sep 1;142:345-9. doi: 10.1016/j.drugalcdep.2014.06.008.
139. Cannabis-associated Myocardial Infarction in a Young Man with Normal Coronary Arteries. Hodcroft CJ, Rossiter MC, Buch AN. / J Emerg Med. 2014 Sep;47(3):277-81. doi: 10.1016/j.jemermed.2013.11.077.
140. Marijuana use and achievement of abstinence from alcohol and other drugs among people with substance dependence: a prospective cohort study. Mojarrad M, Samet JH, Cheng DM, Winter MR, Saitz R. / Drug Alcohol Depend. 2014 Sep 1;142:91-7. doi: 10.1016/j.drugalcdep.2014.06.006.
141. Suicidal ideation and substance use among adolescents and young adults: a bidirectional relation? Zhang X, Wu LT. / Drug Alcohol Depend. 2014 Sep 1;142:63-73. doi: 10.1016/j.drugalcdep.2014.05.025.
142. A randomized controlled trial of a brief motivational enhancement for non-treatment-seeking adolescent cannabis users. de Gee EA, Verdurmen JE, Bransen E, de Jonge JM, Schippers GM. / J Subst Abuse Treat. 2014 Sep;47(3):181-8. doi: 10.1016/j.jsat.2014.05.001.
143. Understanding the etiology and management of HIV-associated peripheral neuropathy. Stavros K, Simpson DM. / Curr HIV/AIDS Rep. 2014 Sep;11(3):195-201. doi: 10.1007/s11904-014-0211-2.
144. Medicinal cannabis: Time to lighten up? Juurlink DN. / CMAJ. 2014 Sep 2;186(12):897-8. doi: 10.1503/cmaj.140309.
145. New medical marijuana regulations: the coming storm. Kahan M, Srivastava A. / CMAJ. 2014 Sep 2;186(12):895-6. doi: 10.1503/cmaj.131821.
146. Patterns of concurrent substance use among nonmedical ADHD stimulant users: results from the National Survey on Drug Use and Health. Chen LY, Crum RM, Martins SS, Kaufmann CN, Strain EC, Mojtabai R. / Drug Alcohol Depend. 2014 Sep 1;142:86-90. doi: 10.1016/j.drugalcdep.2014.05.022.
147. Cycling-related crash risk and the role of cannabis and alcohol: a case-crossover study. Asbridge M, Mann R, Cusimano MD, Tallon JM, Pauley C, Rehm J. / Prev Med. 2014 Sep;66:80-6. doi: 10.1016.
148. Multiple health risk behaviour in Czech adolescents: Family, school and geographic factors. Kážmér L, Dzúrová D, Csémy L, Spilková J. / Health Place. 2014 Sep;29:18-25. doi: 10.1016/j.healthplace.2014.05.009.
149. Addressing adolescent substance use in a paediatric health-care setting. Phillips NL, Milne B, Silsbury C, Zappia P, Zehetner A, Klineberg E, Towns S, Steinbeck K. / J Paediatr Child Health. 2014 Sep;50(9):726-31. doi: 10.1111/jpc.12622.
150. Does adolescent weight status predict problematic substance use patterns? Lanza HI, Grella CE, Chung PJ. / Am J Health Behav. 2014 Sep;38(5):708-16. doi: 10.5993/AJHB.38.5.8.
151. Do reward-processing deficits in schizophrenia-spectrum disorders promote cannabis use? An investigation of physiological response to natural rewards and drug cues. Cassidy CM, Brodeur MB, Lepage M, Malla A. / J Psychiatry Neurosci. 2014 Sep;39(5):339-47.
152. Dedicated ‘cannabis only’ treatment clinics in New South Wales, Australia: Client and treatment characteristics and associations with first-time treatment seeking. Copeland J, Allsop D. / Drug Alcohol Rev. 2014 Sep;33(5):565-71. doi: 10.1111/dar.12166.
153. Catechol-O-methyltransferase gene methylation and substance use in adolescents: the TRAILS study. van der Knaap LJ, Schaefer JM, Franken IH, Verhulst FC, van Oort FV, Riese H. / Genes Brain Behav. 2014 Sep;13(7):618-25. doi: 10.1111/gbb.12147.
154. Detection and prevalence of drug use in arrested drivers using the Dräger Drug Test 5000 and Affiniton DrugWipe oral fluid drug screening devices. Logan BK, Mohr AL, Talpins SK. / J Anal Toxicol. 2014 Sep;38(7):444-50. doi: 10.1093/jat/bku050.
155. Cross-substitution of Δ(9)-tetrahydrocannabinol and JWH-018 in drug discrimination in rats. Wiley JL, Lefever TW, Cortes RA, Marusich JA. / Pharmacol Biochem Behav. 2014 Sep;124:123-8. doi: 10.1016/j.pbb.2014.05.016.
156. Association between cannabis use and schizotypal dimensions–a meta-analysis of cross-sectional studies. Szoke A, Galliot AM, Richard JR, Ferchiou A, Baudin G, Leboyer M, Schürhoff F. / Psychiatry Res. 2014 Sep 30;219(1):58-66. doi: 10.1016/j.psychres.2014.05.008.
157. Web-based screening and brief intervention for student marijuana use in a university health center: pilot study to examine the implementation of eCHECKUP TO GO in different contexts. Palfai TP, Saitz R, Winter M, Brown TA, Kypri K, Goodness TM, O’Brien LM, Lu J. / Addict Behav. 2014 Sep;39(9):1346-52. doi: 10.1016/j.addbeh.2014.04.025.
158. We do not smoke but some of us are more susceptible than others: a multilevel analysis of a sample of Canadian youth in grades 9 to 12. Kaai SC, Brown KS, Leatherdale ST, Manske SR, Murnaghan D. // Addict Behav. 2014 Sep;39(9):1329-36. doi: 10.1016/j.addbeh.2014.04.015.
159. Acculturation and perceived discrimination: predictors of substance use trajectories from adolescence to emerging adulthood among Hispanics. Unger JB, Schwartz SJ, Huh J, Soto DW, Baezconde-Garbanati L. / Addict Behav. 2014 Sep;39(9):1293-6. doi: 10.1016/j.addbeh.2014.04.014.
160. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Ling W, Chang L, Hillhouse M, Ang A, Striebel J, Jenkins J, Hernandez J, Olaer M, Mooney L, Reed S, Fukaya E, Kogachi S, Alicata D, Holmes N, Esagoff A. / Addiction. 2014 Sep;109(9):1489-500. doi: 10.1111/add.12608.
161. Prenatal drug exposure, behavioral problems, and drug experimentation among african-american urban adolescents. Wang Y, Buckingham-Howes S, Nair P, Zhu S, Magder LS, Black MM. / J Adolesc Health. 2014 Sep;55(3):423-31. doi: 10.1016/j.jadohealth.2014.02.021.
162. Feasibility of text messaging for ecological momentary assessment of marijuana use in college students. Phillips MM, Phillips KT, Lalonde TL, Dykema KR. / Psychol Assess. 2014 Sep;26(3):947-57. doi: 10.1037/a0036612.
163. Inhibition during early adolescence predicts alcohol and marijuana use by late adolescence. Squeglia LM, Jacobus J, Nguyen-Louie TT, Tapert SF. / Neuropsychology. 2014 Sep;28(5):782-90. doi: 10.1037/neu0000083.
164. Hardcore adolescent smokers? An examination of the hardening hypothesis by using survey data from two norwegian samples collected eight years apart. von Soest T, Pedersen W. / Nicotine Tob Res. 2014 Sep;16(9):1232-9. doi: 10.1093/ntr/ntu058.
165. Heavy drinking and alcohol-related injuries in college students. Moure-Rodríguez L, Caamaño-Isorna F, Doallo S, Juan-Salvadores P, Corral M, Rodríguez-Holguín S, Cadaveira F. / Gac Sanit. 2014 Sep-Oct;28(5):376-80. doi: 10.1016/j.gaceta.2014.02.017.
166. Cannabis abstinence during treatment and one-year follow-up: relationship to neural activity in men. Kober H, DeVito EE, DeLeone CM, Carroll KM, Potenza MN. / Neuropsychopharmacology. 2014 Sep;39(10):2288-98. doi: 10.1038/npp.2014.82.
167. Elevated homocysteine level in first-episode schizophrenia patients–the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Misiak B, Frydecka D, Slezak R, Piotrowski P, Kiejna A. Metab Brain Dis. 2014 Sep;29(3):661-70. doi: 10.1007/s11011-014-9534-3.
168. The effect of noncognitive traits on health behaviours in adolescence. Mendolia S, Walker I. / Health Econ. 2014 Sep;23(9):1146-58. doi: 10.1002/hec.3043.
169. Detainees in police custody in the Paris, France area: medical data and high-risk situations (a prospective study over 1 year). Chariot P, Beaufrère A, Denis C, Dang C, Vincent R, Boraud C. / Int J Legal Med. 2014 Sep;128(5):853-60. doi: 10.1007/s00414-014-0990-4.
170. Medical marijuana and driving: a review. Neavyn MJ, Blohm E, Babu KM, Bird SB. / J Med Toxicol. 2014 Sep;10(3):269-79. doi: 10.1007/s13181-014-0393-4.
171. Drug Policy Governance in the UK: Lessons from changes to and debates concerning the classification of cannabis under the 1971 Misuse of Drugs Act. Monaghan M. / Int J Drug Policy. 2014 Sep;25(5):1025-30. doi: 10.1016/j.drugpo.2014.02.001.
172. Social norms in the development of adolescent substance use: a longitudinal analysis of the International Youth Development Study. Eisenberg ME, Toumbourou JW, Catalano RF, Hemphill SA. / J Youth Adolesc. 2014 Sep;43(9):1486-97. doi: 10.1007/s10964-014-0111-1..
173. Prevalence of illicit drug use in pregnant women in a Wisconsin private practice setting. Schauberger CW, Newbury EJ, Colburn JM, Al-Hamadani M. / Am J Obstet Gynecol. 2014 Sep;211(3):255.e1-4. doi: 10.1016/j.ajog.2014.03.023.
174. Physical activity and cannabis cessation. Irons JG, Babson KA, Bergeria CL, Bonn-Miller MO. / Am J Addict. 2014 Sep-Oct;23(5):485-92. doi: 10.1111/j.1521-0391.2014.12135.x.
175. Cognitive performance profiles by latent classes of drug use. Harrell PT, Mancha BE, Martins SS, Mauro PM, Kuo JH, Scherer M, Bolla KI, Latimer WW. / Am J Addict. 2014 Sep-Oct;23(5):431-9. doi: 10.1111/j.1521-0391.2014.12124.x.
176. Role of personal and family factors in alcohol and substance use among adolescents: an international study with focus on developing countries. Atilola O, Stevanovic D, Balhara YP, Avicenna M, Kandemir H, Knez R, Petrov P, Franic T, Vostanis P. / J Psychiatr Ment Health Nurs. 2014 Sep;21(7):609-17. doi: 10.1111/jpm.12133.
177.[Clinical prognosis of schizophrenic patients with cannabis addiction : Between nihilism and hope]. Schnell T. / Nervenarzt. 2014 Sep;85(9):1084-92. doi: 10.1007/s00115-013-3926-1. German.
178. The protective effects of neighborhood collective efficacy on adolescent substance use and violence following exposure to violence. Fagan AA, Wright EM, Pinchevsky GM. / J Youth Adolesc. 2014 Sep;43(9):1498-512. doi: 10.1007/s10964-013-0049-8.
179. Concordant and discordant alcohol, tobacco, and marijuana use as predictors of marital dissolution. Leonard KE, Smith PH, Homish GG. / Psychol Addict Behav. 2014 Sep;28(3):780-9. doi: 10.1037/a0034053.
180. Response inhibition and elevated parietal-cerebellar correlations in chronic adolescent cannabis users. Behan B, Connolly CG, Datwani S, Doucet M, Ivanovic J, Morioka R, Stone A, Watts R, Smyth B, Garavan H. / Neuropharmacology. 2014 Sep;84:131-7. doi: 10.1016/j.neuropharm.2013.05.027.
